Abstract: A process is provided for the detection and identification of human antibody types which are specific for antigens such as platelet glycoproteins and Human Leukocyte Antigen (HLA). The process aids in detecting and identifying antibody types from a patient sample which are specific for a plurality of known glycoprotein types attached to a solid support, each glycoprotein type unique from each other and separated from each other.

Abstract: A storable biotransformation mixture that can oxidize a drug, comprising a cytochrome P450 enzyme, an electron donor; and, a buffer solution. In a preferred embodiment the mixture also contains liposomes, cytochrome b.sub.5 and NADPH-P450 reductase as the electron donor. The mixture is storable at a temperature less than 8.degree. C. to for at least two weeks and is able to oxidize a drug after storage.

Abstract: A homogeneous fluorescence-based nucleic acid detection and quantitation system is provided to measure nucleic acid in protein solutions. The process relies on the intercalation of a non-fluorescent dye into a double-stranded nucleic acid helix or single-stranded nucleic acid. The dye fluoresces after intercalation and the intensity is a direct measurement of the amount of nucleic acid present in the sample.

Abstract: The present invention is based on the degradation of a fluorescence labeled nucleic acid such as DNA (F-DNA), RNA (F-RNA) or DNA/RNA substrate. The label may be covalently attached to the relatively high volume substrate at one position or many positions. The nucleic acid is then put in contact with another substance and activity is detected by Fluorescence Polarization.

Abstract: A mapping method for producing an infra-red map utilizing IR coatings on substrates such as microscope slides. The invisible map can be used for positioning a microscope platform or for locating microscopic objects without interference from visible or ultraviolet light.

Abstract: The present invention provides a process of transfecting a cell with a polynucleotide mixed with one or more amphipathic compounds and an effective amount of a DNA-binding protein. Exemplary and preferred DNA-binding proteins are H1, H2A, and H2B. Exemplary and preferred amphipathic compounds are cationic amphipathic compounds.

Abstract: The present invention is directed to determining the presence of antibodies from a patient's blood which are specific for HLA Class I antigens and/or platelet glycoproteins. The invention provides for a method and kit for diagnosing platelet disorders in an easy to use format. The method and kit employ a solid support, such as microtiter plate wells, that are coated with the HLA and glycoprotein antigens. A sample of the patient's blood is added to the coated wells and allowed to react, then spectrophotometric detection of antibodies provides diagnostic quantitation.